NLRP3 and atherosclerosis: Moreover, pharmacological inhibition of NLRP3 using MCC950, a specific NLRP3 inhibitor, significantly decreased both atherosclerotic plaque size and necrotic core formation in Apoe+ mice with STZ-induced diabetes, highlighting NLRP3 as a potential therapeutic target in diabetes-associated atherosclerosis [56].